Browse > Article
http://dx.doi.org/10.4062/biomolther.2012.095

Emerging Roles of Human Prostatic Acid Phosphatase  

Kong, Hoon Young (Department of Molecular Biology, Institute of Nanosensor and Biotechnology, Dankook University)
Byun, Jonghoe (Department of Molecular Biology, Institute of Nanosensor and Biotechnology, Dankook University)
Publication Information
Biomolecules & Therapeutics / v.21, no.1, 2013 , pp. 10-20 More about this Journal
Abstract
Prostate cancer is one of the most prevalent non-skin related cancers. It is the second leading cause of cancer deaths among males in most Western countries. If prostate cancer is diagnosed in its early stages, there is a higher probability that it will be completely cured. Prostatic acid phosphatase (PAP) is a non-specific phosphomonoesterase synthesized in prostate epithelial cells and its level proportionally increases with prostate cancer progression. PAP was the biochemical diagnostic mainstay for prostate cancer until the introduction of prostate-specific antigen (PSA) which improved the detection of early-stage prostate cancer and largely displaced PAP. Recently, however, there is a renewed interest in PAP because of its usefulness in prognosticating intermediate to high-risk prostate cancers and its success in the immunotherapy of prostate cancer. Although PAP is believed to be a key regulator of prostate cell growth, its exact role in normal prostate as well as detailed molecular mechanism of PAP regulation is still unclear. Here, many different aspects of PAP in prostate cancer are revisited and its emerging roles in other environment are discussed.
Keywords
Prostatic acid phosphatase (PAP); Prostate cancer; Biomarker; Prognosis; Diagnosis; Immunotherapy;
Citations & Related Records
Times Cited By KSCI : 1  (Citation Analysis)
연도 인용수 순위
1 Gupta, A., Lotan, Y., Ashfaq, R., Roehrborn, C. G., Raj, G. V., Aragaki, C. C., Montorsi, F. and Shariat, S. F. (2009) Predictive value of the differential expression of the urokinase plasminogen activation axis in radical prostatectomy patients. Eur. Urol. 55, 1124-1133.   DOI   ScienceOn
2 Gutman, A. B. and Gutman, E. B. (1938) An "acid" phosphatase occurring in the serum of patients with metastasizing carcinoma of the prostate gland. J. Clin. Invest. 17, 473-478.   DOI
3 Harvey, A. M., Grice, B., Hamilton, C., Truong, L. D., Ro, J. Y., Ayala, A. G. and Zhai, Q. J. (2010) Diagnostic utility of P504S/p63 cocktail, prostate-specific antigen, and prostatic acid phosphatase in verifying prostatic carcinoma involvement in seminal vesicles: a study of 57 cases of radical prostatectomy specimens of pathologic stage pT3b. Arch. Pathol. Lab. Med. 134, 983-988.
4 Hassan, M. I., Aijaz, A. and Ahmad, F. (2010) Structural and functional analysis of human prostatic acid phosphatase. Expert. Rev. Anticancer Ther. 10, 1055-1068.   DOI   ScienceOn
5 Hobisch, A., Eder, I. E., Putz, T., Horninger, W., Bartsch, G., Klocker, H. and Culig Z. (1998) Interleukin-6 regulates prostate-specific protein expression in prostate carcinoma cells by activation of the androgen receptor. Cancer Res. 58, 4640-4645.
6 Hong, S., Klein, E. A., Das Gupta, J., Hanke, K., Weight, C. J., Nguyen, C., Gaughan, C., Kim, K. A., Bannert, N., Kirchhoff, F., Munch, J. and Silverman, R. H. (2009) Fibrils of prostatic acid phosphatase fragments boost infections with XMRV (xenotropic murine leukemia virus-related virus), a human retrovirus associated with prostate. J. Virol. 83, 6995-7003.   DOI   ScienceOn
7 Hsing, A. W. and Chokkalingam, A. P. (2006) Prostate cancer epidemiology. Front. Biosci. 11, 1388-1413.   DOI   ScienceOn
8 Huang, C. L., Brassil, D., Rozzell, M., Schellhammer, P. F. and Wright, G. L. Jr. (1993) Comparison of prostate secretory protein with prostate specific antigen and prostatic acid phosphatase as a serum biomarker for diagnosis and monitoring patients with prostate carcinoma. Prostate 23, 201-212.   DOI   ScienceOn
9 Hubert, R. S., Vivanco, I., Chen, E., Rastegar, S., Leong, K., Mitchell, S. C., Madraswala, R., Zhou, Y., Kuo, J., Raitano, A. B., Jakobovits, A., Saffran, D. C. and Afar, D. E. (1999) STEAP: A prostate-specific cell-surface antigen highly expressed in human prostate tumors. Proc. Natl. Acad. Sci. USA 96, 14523-14528.   DOI
10 Hurt, J. K., Fitzpatrick, B. J. Norris-Drouin, J. and Zylka, M. J. (2012a) Secretion and N-linked glycosylation are required for prostatic acid phosphatase catalytic and antinociceptive activity. PLoS One 7, e32741.   DOI
11 Hurt, J. K. and Zylka, M. J. (2012b) PAPupuncture has localized and long-lasting antinociceptive effects in mouse models of acute and chronic pain. Mol. Pain. 8, 28.   DOI
12 Jakob, C. G., Lewinski, K., Kuciel, R., Ostrowski, W. and Lebioda, L. (2000) Crystal structure of human prostatic acid phosphatase. Prostate 42, 211-218.   DOI
13 Kong, H. Y., Lee, H. J. and Byun, J. (2011) Roles of prostatic acid phosphatase in prostate cancer. J. Life Sci. 21, 893-900.   DOI   ScienceOn
14 Korkmaz, C. G., Korkmaz, K. S., Kurys, P., Elbi, C., Wang, L., Klokk, T. I., Hammarstrom, C., Troen, G., Svindland, A., Hager, G. L. and Saatcioglu, F. (2005) Molecular cloning and characterization of STAMP2, an androgen-regulated six transmembrane protein that is overexpressed in prostate cancer. Oncogene 24, 4934-4945.   DOI   ScienceOn
15 Kuciel, R., Bakalova, A., Mazurkiewicz, A., Bilska, A. and Ostrowski, W. (1990) Is the subunit of prostatic phosphatase active?Reversible denaturation of prostatic acid phosphatase. Biochem. Int. 22, 329-334.   DOI   ScienceOn
16 Korkmaz, K. S.,, Elbi, C., Korkmaz, C. G., Loda, M., Hager, G. L. and Saatcioglu, F. (2002) Molecular cloning and characterization of STAMP1, a highly prostate-specific six transmembrane protein that is overexpressed in prostate cancer. J. Biol. Chem. 277, 36689-36696.   DOI   ScienceOn
17 Kraus, T. S., Cohen, C. and Siddiqui, M. T. (2010) Prostate-specific antigen and hormone receptor expression in male and female breast carcinoma. Diagn. Pathol. 5, 63.   DOI   ScienceOn
18 Kristiansen, G., Fritzsche, F. R., Wassermann, K., Jäger, C., Tölls, A., Lein, M., Stephan, C., Jung, K., Pilarsky, C., Dietel, M. and Moch, H. (2008) GOLPH2 protein expression as a novel tissue biomarker for prostate cancer: implications for tissue-based diagnostics. Br. J. Cancer 99, 939-948.   DOI   ScienceOn
19 Larne, O., Martens-Uzunova, E., Hagman, Z., Edsjo, A., Lippolis, G., den Berg, M. S., Bjartell, A., Jenster, G. and Ceder, Y. (2012) miQ - a novel microRNA based diagnostic and prognostic tool for prostate cancer. Int. J. Cancer doi: 10.1002/ijc.27973. [Epub ahead of print]   DOI   ScienceOn
20 Lee, H., Chu, T. M., Li, S. S. and Lee, C. L. (1991) Homodimer and heterodimer subunits of human prostatic acid phosphatase. Biochem. J. 277, 759-765.   DOI
21 Lee, W. H., Morton, R. A., Epstein, J. I., Brooks, J. D., Campbell, P. A., Bova, G. S., Hsieh, W. S., Isaacs, W. B. and Nelson, W. G. (1994) Cytidine methylation of regulatory sequences near the pi-class glutathione S-transferase gene accompanies human prostatic carcinogenesis. Proc. Natl. Acad. Sci. USA 91, 11733-11737.   DOI   ScienceOn
22 Li, T. S. and Beling, C. G. (1973) Isolation and characterization of two specific antigens of human seminal plasma. Fertil. Steril. 24, 134-144.   DOI
23 Liu, B. Q., Wu, Y. D., Li, P. H., Wei, J. X., Zhang, T. and Liu R. L. (2007) Prostate cancer antigen-1 as a potential novel marker for prostate cancer. Asian J. Androl. 9, 821-826.   DOI   ScienceOn
24 Lin, M. F., Garcia-Arenas, R., Xia, X. Z., Biela, B. and Lin, F. F. (1994) The cellular level of prostatic acid phosphatase and the growth of human prostate carcinoma cells. Differentiation 57, 143-149.   DOI   ScienceOn
25 Lin, M. F., Lee, M. S., Zhou, X. W., Andressen, J. C., Meng, T. C., Johansson, S. L., West, W. W., Taylor, R. J., Anderson, J. R. and Lin, F. F. (2001) Decreased expression of cellular prostatic acid phosphatase increases tumorigenicity of human prostate cancer cells. J. Urol. 166, 1943-1950.   DOI   ScienceOn
26 Lin, M. F., Meng, T. C., Rao, P. S., Chang, C., Schonthal, A. H. and Lin, F. F. (1998) Expression of human prostatic acid phosphatase correlates with androgen-stimulated cell proliferation in prostate cancer cell lines. J. Biol. Chem. 273, 5939-5947.   DOI   ScienceOn
27 Lubaroff, D. M. (2012) Prostate cancer vaccines in clinical trials. Expert. Rev. Vaccines 11, 857-868.   DOI   ScienceOn
28 Madu, C. O. and Lu, Y. (2010) Novel diagnostic biomarkers for prostate cancer. J. Cancer 1, 150-177.
29 Makarov, D. V., Loeb, S., Getzenberg, R. H. and Partin, A. W. (2009) Biomarkers for prostate cancer. Ann. Rev. Medicine 60, 139-151.   DOI   ScienceOn
30 McNeel, D. G., Dunphy, E.J., Davies, J. G., Frye, T. P., Johnson, L. E., Staab, M. J., Horvath, D. L., Straus, J., Alberti, D., Marnocha, R., Liu, G., Eickhoff, J. C. and Wilding, G. (2009) Safety and immunological efficacy of a DNA vaccine encoding prostatic acid phosphatase in patients with D0 prostate cancer. J. Clin. Oncol. 27, 4047-4054.   DOI   ScienceOn
31 Okar, D. A., Live, D. H., Devany, M. H. and Lange, A. J. (2000) Mechanism of the bisphosphatase reaction of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase probed by (1)H-(15)N NMR spectroscopy. Biochemistry 39, 9754-9762.   DOI   ScienceOn
32 Meng, T. C., Lee, M. S. and Lin, M. F. (2000) Interaction between protein tyrosine phosphatase and protein tyrosine kinase is involved in androgen-promoted growth of human prostate cancer cells. Oncogene19, 2664-2677.   DOI   ScienceOn
33 Merrick, G. S., Butler, W. M., Wallner, K. E., Allen, Z., DeFilippo, J. L. and Adamovich, E. (2005) Enzymatic prostatic acid phosphatase in the clinical staging of patients diagnosed with prostate cancer. W. V. Med. J. 101, 116-119.
34 Munch, J., Rücker, E, Ständker, L., Adermann, K., Goffinet, C., Schindler, M., Wildum, S., Chinnadurai, R., Rajan, D., Specht, A., Giménez-Gallego, G., Sánchez, P. C., Fowler, D. M., Koulov, A., Kelly, J. W., Mothes, W., Grivel, J. C., Margolis, L., Keppler, O. T., Forssmann, W. G. and Kirchhoff, F. (2007) Semen-derived amyloid-fibrils drastically enhance HIV infection. Cell 131, 1059-1071.   DOI   ScienceOn
35 Ortlund, E., LaCount, M. W. and Lebioda, L. (2003) Crystal structure of human prostatic acid phosphatase in complex with a phosphate ion and a-benzylaminobenzylphosphonic acid update the mechanistic picture and offer new insight into inhibitor design. Biochemistry 42, 383-389.   DOI   ScienceOn
36 Ostanin, K., Saeed, A. and Van Etten, R. L. (1994) Heterologous expression of human prostatic acid phosphatase and site-directed mutagenesis of the enzyme active site. J. Biol. Chem. 269, 8971-8978.
37 Ostrowski, W. S. and Kuciel, R. (1994) Human prostatic acid phosphatase: selected properties and practical applications. Clin. Chim. Acta. 226, 121-129.   DOI   ScienceOn
38 Porvari, K., Kurkela, R., Kivinen, A. and Vihko, P. (1995) Differential androgen regulation of rat prostatic acid phosphatase transcripts. Biochem. Biophys. Res. Commun. 213, 861-868.   DOI   ScienceOn
39 Reif, A. E., Schlesinger, R. M., Fish, C. A. and Robinson, C. M. (1973) Acid phosphatase isoenzymes in cancer of the prostate. Cancer 31, 689-699.   DOI
40 Quintero, I. B., Araujo, C. L., Pulkka, A. E., Wirkkala, R. S., Herrala, A. M., Eskelinen, E. L., Jokitalo, E., Hellström, P. A., Tuominen, H. J., Hirvikoski, P. P. and Vihko, P. T. (2007) Prostatic acid phosphatase is not a prostate specific target. Cancer Res. 67, 6549-6554.   DOI   ScienceOn
41 Reiter, R. E., Gu, Z., Watabe, T., Thomas, G., Szigeti, K., Davis, E., Wahl, M., Nisitani, S., Yamashiro, J., Le Beau, M. M., Loda, M. and Witte, O. N. (1998) Prostate stem cell antigen: a cell surface marker overexpressed in prostate cancer. Proc. Natl. Acad. Sci. USA 95, 1735-1740.   DOI
42 Rogers, C. G., Yan, G., Zha, S., Gonzalgo, M. L., Isaacs, W. B., Luo, J., De Marzo, A. M., Nelson, W. G. and Pavlovich, C. P. (2004) Prostate cancer detection on urinalysis for alpha methylacyl coenzyme A racemase protein. J. Urol. 172, 1501-1503.   DOI   ScienceOn
43 Roiko, K., Jänne, O. A. and Vihko, P. (1990) Primary structure of rat secretory acid phosphatase and comparison to other acid phosphatase. Gene 89, 223-229.   DOI   ScienceOn
44 Ronnberg, L., Vihko, P., Sajanti, E. and Vihko, R. (1981). Clomiphene citrate administration to normogonadotrophic subfertile men: blood hormone changes and activation of acid phosphatase in seminal fluid. Int. J. Androl. 4, 372-378.   DOI
45 Roth, T. J., Sheinin, Y., Lohse, C. M., Kuntz, S. M., Frigola, X., Inman, B. A., Krambeck, A. E., McKenney, M. E., Karnes, R. J., Blute. M. L., Cheville, J. C., Sebo, T. J. and Kwon, E. D. (2007) B7-H3 ligand expression by prostate cancer: a novel marker of prognosis and potential target for therapy. Cancer Res. 67, 7893-7900.   DOI   ScienceOn
46 Shan, J., Porvari, K. and Vihko, P. (2005) GAAAATATGATA-like elements in androgen-associated regulation of the prostatic acid phosphatasegene. J. Steroid. Biochem. Mol. Biol. 96, 245-249.   DOI   ScienceOn
47 Rubenstein, M., Hollowell, C. M. and Guinan, P. (2012) Differentiated prostatic antigen expression in LNCaP cells following treatment with bispecific antisense oligonucleotides directed against BCL-2 and EGFR. Med. Oncol. 29, 835-841.   DOI   ScienceOn
48 Saito, T., Hara, N., Kitamura, Y. and Komatsubara, S. (2007) Prostate-specific antigen/ prostatic acid phosphatase ratio is significant prognostic factor in patients with stage IV prostate cancer. Urology 70, 702-705.   DOI   ScienceOn
49 Shan. J., Porvari, K., Kivinen, A., Patrikainen, L., Halmekytö, M., Jänne, J. and Vihko, P. (2003) Tissue-specific expression of the prostatic acid phosphatase promoter constructs. Biochem. Biophys. Res. Commun. 311, 864-869.   DOI   ScienceOn
50 Shariat, S. F., Scherr, D. S., Gupta, A., Bianco, F. J. Jr, Karakiewicz, P. I., Zeltser, I. S., Samadi, D. B. and Akhavan, A. (2011) Emerging biomarkers for prostate cancer diagnosis, staging, and prognosis. Arch. Esp. Urol. 64, 681-694.
51 Sharma, S. and Juffer, A. H. (2009) Hydrolysis of phosphohistidine in water and in prostatic acid phosphatase. Chem. Commun (Camb). 14, 6385-6387.
52 Sheftic, S., R., Snell, J., M., Jha, S. and Alexandrescu, A. T. (2012) Inhibition of semen-derived enhancer of virus infection (SEVI) fibrillogenesis by zinc and copper. Eur. Biophys J. 41, 695-704.   DOI
53 Sheridan, T., Herawi, M., Epstein, J. I. and Illei, P. B. (2007) The role of P501S and PSA in diagnosis of metastatic adenocarcinoma of the prostate. Am. J. Surg. Pathol. 31, 1351-1355.   DOI   ScienceOn
54 Azumi, N., Traweek, S. T. and Battifora, H. (1991) Prostatic acid phosphatase in carcinoid tumors: Immunohistochemical and immunoblot studies. Am. J. Surg. Pathol. 15, 758-790.
55 Abrahamsson, P. A., Lilja, H., Falkmer, S. and Wadstrom, L. B. (1988) Immunohistochemical distribution of the three predominant secretory proteins in the parenchyma of hyperplastic and neoplastic prostate glands. Prostate 12, 39-46.   DOI   ScienceOn
56 Afzal, S., Ahmad, M., Mushtaq, S., Mubarik, A., Qureshi, A. H. and Khan, S. A. (2003) Morphological features correlation with serum tumor markers in prostatic carcinoma. J. Coll. Physicians. Surg. Pak. 13, 511-514.
57 Antonarakis, E. S. and Drake, C. G., (2010) Current status of immunological therapies for prostate cancer. Curr. Opin. Urol. 20, 241-246.   DOI   ScienceOn
58 Batta, A., Panag, KMDS. and Singh, J. (2012) Diagnosis of prostate cancer --- Role of biomarkers. Int. J. Cur. Biomed. Phar. Res. 2, 339-345.
59 Batta, A., Panag, KMDS. and Singh, J. (2012) Diagnosis of prostate cancer --- Role of biomarkers. Int. J. Cur. Biomed. Phar. Res. 2, 339-345.
60 Brawer, M. K., Chetner, M. P., Beatie, J., Buchner, D. M., Vessella, R. L. and Lange, P. H. (1992) Screening for prostatic carcinoma with prostate specific antigen. J. Urol. 147, 841-845.   DOI
61 Solin, T., Kontturi, M., Pohlmann, R. and Vihko, P. (1990) Gene expression and prostate specificity of human prostatic acid phosphatase (PAP) : evaluation by RNA blot analyses. Biochim. Biophys. Acta. 1048, 72-77.   DOI   ScienceOn
62 Sims, R. B. (2012) Development of sipuleucel-T: autologous cellular immunotherapy for the treatment of metastatic castrate resistant prostate cancer. Vaccine 30, 4394-4397.   DOI   ScienceOn
63 Singh, G., Adaikan, P. G. and Ng, Y. K. (1996) Is seminal prostatic acid phosphatase a reliable marker for male infertility? Singapore Med. J. 37, 598-599.
64 Small, E. J., Schellhammer, P. F., Higano, C. S., Redfern, C. H., Nemunaitis, J. J., Valone, F. H., Verjee, S. S., Jones, L. A. and Hershberg, R. M. (2006) Placebo-controlled Phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J. Clin. Oncol. 24, 3089-3094.   DOI   ScienceOn
65 Sowa, N. A., Street, S. E., Vihko, P. and Zylka, M. J. (2010) Prostatic acid phosphatase reduces thermal sensitivity and chronic pain sensitization by depleting phosphatidylinositol 4,5-bisphosphate. J. Neurosci. 30, 10282-10293.   DOI   ScienceOn
66 Sowa, N. A., Vadakkan, K. I. and Zylka, M. J. (2009) Recombinant mouse PAP has pH-dependent ectonucleotidase activity and acts through A(1)-adenosine receptors to mediate antinociception. PLoS One 4, e4248.   DOI   ScienceOn
67 Sreekumar, A., Poisson, L. M., Rajendiran, T. M., Khan, A. P., Cao, Q., Yu, J., Laxman, B., Mehra, R., Lonigro, R. J., Li, Y., Nyati, M. K., Ahsan, A., Kalyana-Sundaram, S., Han, B., Cao, X., Byun, J., Omenn, G. S., Ghosh, D., Pennathur, S., Alexander, D. C., Berger, A., Shuster, J. R., Wei, J. T., Varambally, S., Beecher, C. and Chinnaiyan, A. M. (2009) Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature 457, 910-914.   DOI   ScienceOn
68 Chen, H., Pong, R. C., Wang, Z. and Hsieh, J. T. (2002) Differential regulation of the human gene DAB2IP in normal and malignant prostatic epithelia: cloning and characterization. Genomics 79, 573-581.   DOI   ScienceOn
69 Bussemakers, M. J., van Bokhoven, A., Verhaegh, G. W., Smit, F. P., Karthaus, H. F., Schalken, J. A., Debruyne, F. M., Ru, N. and Isaacs, W. B. (1999) DD3: a new prostate-specific gene, highly overexpressed in prostate cancer. Cancer Res. 59, 5975-5979.
70 Cheever, M. A. and Higano, C. S. (2011) PROVENGE (Sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccine. Clin. Cancer Res. 17, 3520-3526.   DOI
71 Collins, K. A. and Bennett, A. T. (2011) Persistence of spermatozoa and prostatic acid phosphatase in specimens from decreased individuals during varied postmortem intervals. Am. J. Forensic Med. Pathol. 22, 228-232.
72 Coussens, L. M. and Werb, Z. (2002) Inflammation and cancer. Nature 420, 860-867.   DOI   ScienceOn
73 Dave, B. N. and Rindani, T. H. (1988) Acid phosphatase activity in human semen. Int. J. Fertil. 33, 45-47.
74 Deftos, L. J. (1998) Granin-A, parathyroid hormone-related protein, and calcitonin gene products in neuroendocrine prostate cancer. Prostate Suppl. 8, 23-31.
75 Drake, C. G. (2010) Prostate cancer as a model for tumour immunotherapy. Nat. Rev. Immunol. 10, 580-593.   DOI   ScienceOn
76 Drake, C. G. (2012) Interdisciplinary critique of sipuleucel-T as immunotherapy in castration-resistant prostate cancer. J. Natl. Cancer Inst. 104, 1422.
77 Erbas, H., Erten, O. and Irfanoglu, M. E. (2007) Prostatic acid phosphatase in breast cyst fluid. Malays. J. Pathol. 29, 95-99.
78 Taira, A., Merrick, G., Wallner, K. and Dattoli, M. (2007) Reviving the acid phosphatase test for prostate cancer. Oncology 21, 1003-1010.
79 Stamey, T. A., Yang, N., Hay, A. R., McNeal, J. E., Freiha, F. S. and Redwine, E. (1987) Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N. Engl. J. Med. 317, 909-916.   DOI   ScienceOn
80 Street, S. E., Walsh, P. L., Sowa, N. A., Taylor-Blake, B., Guillot, T. S., Vihko, P., Wightman, R. M. and Zylka, M. J. (2011) PAP and NT5E inhibit nociceptive neurotransmission by rapidly hydrolyzing nucleotides to adenosine. Mol. Pain 7, 80.   DOI
81 Tasken, K. A., Angelsen, A., Svindland, A., Eide, T., Berge, V., Wahlquist, R. and Karlsen, S. (2005) Markers for diagnosis, prediction and prognosis of prostate cancer. Tidsskr. Nor. Laegeforen. 125, 3279-3282.
82 Thompson, T. C., Tahir, S. A., Li, L., Watanabe, M., Naruishi, K., Yang, G., Kadmon, D., Logothetis, C. J., Troncoso, P., Ren, C., Goltsov, A. and Park, S. (2010) The role of caveolin-1 in prostate cancer: clinical implications. Prostate Cancer Prostatic. Dis. 13, 6-11.   DOI   ScienceOn
83 Tian, W., Osawa, M., Horiuchi, H. and Tomita, Y. (2004) Expression of the prolactin-inducible protein (PIP/GCDFP15) gene in benign epithelium and adenocarcinoma of the prostate. Cancer Sci. 95, 491-495.   DOI   ScienceOn
84 Truong, L. D., Kadmon, D., McCune, B. K., Flanders, K. C., Scardino, P. T. and Thompson, T. C. (1993) Association of transforming growth factor-beta 1 with prostate cancer: An immunohistochemical study. Hum. Pathol. 24, 4-9.   DOI   ScienceOn
85 Van Etten, R. L. (1982) Human prostatic acid phosphatase: a histidine phosphatase. Ann. N. Y. Acad. Sci. 390, 27-51.   DOI
86 Gerdes, J., Lemke, H., Baisch, H., Wacker, H. H., Schwab, U. and Stein, H. (1984) Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J. Immunol. 133, 1710-1715.
87 Ercole, C. J., Lange, P. H., Mathisen, M., Chiou, R. K., Reddy, P. K. and Vessella, R. L. (1987) Prostatic specific antigen and prostatic acid phosphatase in the monitoring and staging of patients with prostatic cancer. J. Urol. 138, 1181-1184.   DOI
88 Fang, L.C., Dattoli, M., Taira, A., True, L., Sorace, R. and Wallner K. (2008) Prostatic acid phosphatase adversely affects cause-specific survival in patients with intermediate to high-risk prostate cancer treated with brachytherapy. Urology 71, 146-150.   DOI   ScienceOn
89 Garcia, J. A. (2011) Sipuleucel-T in patients with metastatic castration-resistant prostate cancer: an insight for oncologists. Ther. Adv. Med. Oncol. 3, 101-108.   DOI
90 Gerritsen, W. R. (2012) The evolving role of immunotherapy in prostate cancer. Ann. Oncol. 23, viii22-27.   DOI   ScienceOn
91 Getzenberg, R. H., Pienta, K. J., Huang, E. Y. and Coffey, D. S. (1991) Identification of nuclear matrix proteins in the cancer and normal rat prostate. Cancer Res. 51, 6514-6520.
92 Goldfarb, D. A., Stein, B. S., Shamszadeh, M. and Petersen, R. O. (1986) Age-related changes in tissue level of prostatic acid phosphatase and prostate specific antigen. J. Urol. 136, 1266-1269.   DOI
93 Graddis, T. J., McMahan, C. J., Tamman, J., Page, K. J. and Trager, J. B. (2011) Prostatic acid phosphatase expression in human tissues. Int. J. Clin. Exp. Pathol. 4, 295-306.
94 Gunia, S., Koch, S., May, M., Dietel, M. and Erbersdobler, A. (2009) Expression of prostatic acid phosphatase (PSAP) in transurethral resection specimens of the prostate is predictive of histopathologic tumor stage in subsequent radical prostatectomies. Virchows. Arch. 454, 573-579.   DOI
95 Vieweg, J. and Dannull, J. (2005) Technology insight: vaccine therapy for prostate cancer. Nat. Clin. Pract. Urol. 2, 44-51.   DOI   ScienceOn
96 Van Etten, R. L., Davidson, R., Stevis, P. E., MacArthur, H. and Moore, D. L. (1991) Covalent structure, disulfide binding, and identification of reactive surface and active site residues of human prostatic acid phosphatase. J. Biol. Chem. 266, 2313-2319.
97 Vanaja, D. K., Ballman, K. V., Morlan, B. W., Cheville, J. C., Neumann, R. M., Lieber, M. M., Tindall, D. J. and Young, C. Y. (2006) PDLIM4 repression by hypermethylation as a potential biomarker for prostate cancer. Clin. Cancer Res. 12, 1128-1136.   DOI   ScienceOn
98 Veeramani, S., Yuan, T. C., Chen, S. J., Lin, F. F., Petersen, J. E., Shaheduzzaman, S., Srivastava, S., MacDonald, R. G. and Lin, M. F. (2005) Cellular prostatic acid phosphatase : a protein tyrosine phosphatase involved in androgen-independent proliferation of phosphatase. Endocr. Relat. Cancer 12, 805-822.   DOI   ScienceOn
99 Vihko, P., Herrala, A., Härkönen, P., Isomaa, V., Kaija, H., Kurkela, R., Li, Y., Patrikainen, L., Pulkka, A., Soronen, P. and Torn, S. (2005) Enzymes as modulators in malignant transformation. J. Steroid Biochem. Mol. Biol. 93, 277-283.   DOI   ScienceOn
100 Vihko, P., Kontturi, M. and Korhonen, L. K. (1978) Purification of human prostatic acid phosphatase by affinity chromatography and isoelectric focusing. Part I. Clin. Chem. 24, 466-470.
101 Wang, Y., Harada, M., Yano, H., Ogasawara, S., Takedatsu, H., Arima, Y., Matsueda, S., Yamada, A. and Itoh, K. (2005) Prostatic acid phosphatase as a target molecule in specific immunotherapy for patients with nonprostate adenocarcinoma. J. Immunother. 28, 535-541.   DOI
102 Wikstrom, P., Lissbrant, I. F., Stattin, P., Egevad, L. and Bergh, A. (2002) Endoglin (CD105) is expressed on immature blood vessels and is a marker for survival in prostate cancer. Prostate 51, 268-275.   DOI   ScienceOn
103 Zelivianski, S., Glowacki, R. and Lin, M. F. (2004) Transcriptional activation of the human prostatic acid phosphatase gene by NF-$\kappa B$ via a novel hexanucleotide-binding site. Nucleic. Acid. Res. 32, 3566-3580.   DOI   ScienceOn
104 Winqvist, R., Virkkunen, P., Grzeschik, K. H. and Vihko, P. (1989) Chromosomal localization to 3q21----qter and two TaqI RFLPs of the human prostatic-specific acid phosphatase gene (ACPP). Cytogenet. Cell Genet. 52, 68-71.   DOI
105 Young, A., Palanisamy, N., Siddiqui, J., Wood, D., P., Wei, J., T., Chinnaiyan., A. M., Kunju, L., P. and Tomlins, S. A. (2012) Correlation of Urine TMPRSS2:ERG and PCA3 to ERG+ and Total Prostate Cancer Burden. Am. J. Clin. Pathol. 138, 685-696.   DOI
106 Zelivianski, S., Comeau, D. and Lin, M. F. (1998) Cloning and analysis of the promoter activity of the human prostatic acid phosphatase gene. Biochem. Biophys. Res. Commun. 245, 108-112.   DOI   ScienceOn
107 Zhang, X. Q., Lee, M. S., Zelivianski, S. and Lin, M. F. (2001) Characterization of a prostate-specific tyrosine phosphatase by mutagenesis and expression in human prostate cancer cells. J. Biol. Chem. 276, 2544-2550.   DOI   ScienceOn
108 Zimmermann, H. (2009) Prostatic acid phosphatase, a neglected ectonucleotidase. Purinergic Signal. 5, 273-275   DOI
109 Zylka, M. J., Sowa, N. A., Taylor-Blake, B., Twomey, M. A., Herrala, A., Voikar, V. and Vihko P. (2008) Prostatic acid phosphatase is an ectonucleotidase and suppresses pain by generating adenosine. Neuron 60, 111-122.   DOI   ScienceOn